



ITW

Docket No. CRD-5064

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Michael O'Hara

Serial No. : 10/785,519

Art Unit: 3731

Filed : February 24, 2004

Examiner: Sarah K. Webb

For : RADIOPROTECTIVE COMPOUND COATING FOR MEDICAL
DEVICES

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

May 25, 2006

(Date of Deposit)

Carl J. Evens

(Name of applicant, assignee, or Registered Representative)

/Carl J. Evens/

(Signature)

May 25, 2006

(Date of Signature)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e)
(attached); or
- ☐ Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth
in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2).

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CRD5064/CJE. This form is submitted in triplicate.

Respectfully submitted,

/Carl J. Evens/

Carl J. Evens
Reg. No. 33,874
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2518
DATED: May 25, 2006



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CRD-5064	Application No. 10/785,519
	Applicant Michael O'Hara	
	Filing Date February 24, 2004	Group 3731
	Confirmation No. 8314	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	1	3,929,992	12/30/75	Seghal et al.	424	122
	2	3,959,078	05/25/76	Guire	530	350
	3	4,350,160	09/21/82	Kolesov et al.	227	179.1
	4	4,366,819	01/04/83	Kaster	606	153
	5	4,368,736	01/18/83	Kaster	606	153
	6	4,624,257	11/25/86	Berggren et al.	606	153
	7	4,722,906	02/02/88	Guire	436	501
	8	4,733,665	03/29/88	Palmaz	606	108
	9	4,739,762	04/26/88	Palmaz	623	1.11
	10	4,776,337	10/11/88	Palmaz	623	1.11
	11	4,917,090	04/17/90	Berggren et al.	606	153
	12	4,917,091	04/17/90	Berggren et al.	606	153
	13	5,229,172	07/20/93	Cahalan et al.	427	536
	14	5,234,447	08/10/93	Kaster et al.	606	153
	15	5,308,641	05/03/94	Cahalan et al.	427	2.1
	16	5,350,800	09/27/94	Verhoeven et al.	525	54.2
	17	5,415,938	05/16/95	Cahalan et al.	428	409
	18	5,837,313	11/17/98	Ding et al.	427	2.21
	19	6,099,562	08/08/00	Ding et al.	623	1.46
	20	6,120,536	09/19/00	Ding et al.	623	1.43
	21	6,153,252	11/28/00	Hossainy et al.	427	2.3
	22	6,425,898	07/30/02	Wilson et al.	606	108
	23	2002/0193336 A1	12/19/02	Elkins et al.	514	44

EXAMINER	DATE CONSIDERED
-----------------	------------------------

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CRD-5064	Application No. 10/785,519
	Applicant Michael O'Hara	
	Filing Date February 24, 2004	Group 3731
	Confirmation No. 8314	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	24	98/33443 A1	08/06/98	WO		
	25	02/085253 A1	10/31/02	WO		
	26	2004/107965 A2	12/16/04	WO		
	27	1 243 272 A2	09/25/02	EP		

EXAMINER	DATE CONSIDERED
----------	-----------------

Form PTO-1449 Modified		Docket No. CRD-5064	Application No. 10/785,519
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Michael O'Hara	
U.S. Department of Commerce Patent and Trademark Office		Filing Date February 24, 2004	Group 3731
		Confirmation No. 8314	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	28	Ajroldi, G. et al., "Fluoroelastomers-dependence of relaxation phenomena on composition," POLYMER, 1989, 30, 2180-2187	
	29	Berk, B. C. et al., "Heparins and Glucocorticoids Inhibit Restenosis," J. Am. Coll. Cardiol., 1991, 17, 111B-117B	
	30	Campbell, G. R. and Campbell, J. H., "Phenotypic Modulation of Smooth Muscle Cells in Primary Culture," In: <i>Vascular Smooth Muscle in Culture</i> , Vol. 1, Ch. 4, Boca Raton, FL: CRC, 1987, pp. 39-55	
	31	Campbell, G. R., et al., "Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis," Exp. Mol. Pathol., April 1985, 42(2), 139-162	
	32	Chang, M. W. et al., "Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent," J. Clin. Invest., 1995, 96: 2260-2268	
	33	Clowes, A. W. et al., "Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin," Lab. Invest., 1985, 52(6), 611-616	
	34	Clowes, A. W. et al., "Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration," Circ. Res., 1986, 58(6), 839-845	
	35	Clowes, A. W. et al., "Significance of quiescent smooth muscle migration in the injured rat carotid artery," Circ Res. 1985, 56(1), 139-145	
	36	Clowes, A. W., "Suppression by heparin of smooth muscle cell proliferation in injured arteries," Nature, 1977, 265(5595), 625-626	
	37	Colburn, M. D. et al., "Dose responsive suppression of myointimal hyperplasia by dexamethasone," J. Vasc. Surg., 1992, 15, 510-518	
	38	Currier, J. W. et al., "Colchicine Inhibits Restenosis After Iliac Angioplasty in the Atherosclerotic Rabbit," Supplement to Circulation. Abstracts From the 62 nd Scientific Sessions., 1989, 80(4), Abstract No. 0263	
	39	Deroanne et al., "Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling," Oncogene, 2002, 21(3), 427-436	
	40	Edelman, E. R. et al., "Pathobiologic responses to stenting," Am J. Cardiol. 1998, 81(7A), 4E-6E	
	41	Farb, A. et al., "Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein," Circ. Res., 1997, 80, 542-550	

EXAMINER

DATE CONSIDERED

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CRD-5064	Application No. 10/785,519
		Applicant Michael O'Hara	
		Filing Date February 24, 2004	Group 3731
		Confirmation No. 8314	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	42	Ferns, G. A. A. et al., "Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF," Science, 1991, 253, 1129-1132	
	43	Fischman, D. L. et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease," N. Eng. J. Med., 1994 Aug 25, 331(8), 496-501	
	44	Franklin, S. M. et al., "Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials," Coron Artery Dis. 1993 Mar, 4(3), 232-242	
	45	Fukuyama, J. et al., "Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet," Eur. J. Pharmacol., 1996, 318, 327-332	
	46	Guyton, J. R. et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin," Circ. Res., 1980, 46, 625-634	
	47	Hanson, S. R. et al., "Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone," Proc. Natl. Acad. Sci. USA, 1988, 85, 3184-3188	
	48	Hansson, G. K. et al., "Interferon- γ Inhibits Arterial Stenosis After Injury," Circ., 1991, 84, 1266-1272	
	49	Jonasson, J. et al., "Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury," Proc. Natl. Acad. Sci., 1988, 85, 2303-2306	
	50	Lang, R. J. et al., "Effects of 2,3-butanedione monoxime on whole-cell Ca ²⁺ channel currents in single cells of the guinea-pig taenia caeci," J Physiol. 1991 Feb, 433, 1-24	
	51	Lang, R. J. et al., "Effects of okadaic acid and ATP gamma S on cell length and Ca(2+)-channel currents recorded in single smooth muscle cells of the guinea-pig taenia caeci.," Br. J. Pharmacol., 1991 Oct, 104(2), 331-336	
	52	Liu, M. W. et al., "Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit," Circ., 1990, 81, 1089-1093	
	53	Lundergan, C. F. et al., "Terbinafine inhibits the mitogenic response to platelet-derived growth factor in vitro and neointimal proliferation in vivo," Am. J. Cardiol., 1991, 17(Suppl. B), 132B-136B	
	54	Majesky, M. W. et al., "Heparin regulates smooth muscle S phase entry in the injured rat carotid artery," Circ. Res., 1987, 61, 296-300	

EXAMINER

DATE CONSIDERED

Form PTO-1449 Modified		Docket No. CRD-5064	Application No. 10/785,519
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Michael O'Hara	
U.S. Department of Commerce Patent and Trademark Office		Filing Date February 24, 2004	Group 3731
		Confirmation No. 8314	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	55	Mak, K-H. et al., "Clinical trials to prevent restenosis after percutaneous coronary revascularization," Ann N Y Acad Sci., 1997 Apr 15, 811, 255-84; discussion 284-8. Review	
	56	Marx, S. O. et al., "Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells," Circ. Res., 1995, 76, 412-417	
	57	Mintz, G. S. et al., "Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study," Circulation. 1996 Jul 1, 94(1), 35-43	
	58	Mintz, G. S. et al., "Axial plaque redistribution as a mechanism of percutaneous transluminal coronary angioplasty," Am J Cardiol, 1996 Feb 15, 77(5), 427-430	
	59	Mintz, G. S. et al., "Intravascular Ultrasound Assessment of the Mechanisms and Predictors of Restenosis Following Coronary Angioplasty," J Invasive Cardiol., 1996 Jan, 8(1), 1-14	
	60	Mintz, G. S. et al., "Intravascular ultrasound findings after excimer laser coronary angioplasty," Cathet Cardiovasc Diagn. 1996 Feb, 37(2), 113-118	
	61	Mintz, G. S. et al., "Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularization," J Am Coll Cardiol, 1996 Jun, 27(7), 1678-87	
	62	Mintz, G. S. et al., "Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis," Am J Cardiol. 1996 Aug 14, 78(3A), 18-22	
	63	Mintz, G. S. et al., "Limitations of angiography in the assessment of plaque distribution in coronary artery disease: a systematic study of target lesion eccentricity in 1446 lesions," Circulation. 1996 Mar 1, 93(5), 924-931	
	64	Modern Fluoropolymers, (J. Scheirs, ed.), John Wiley & Sons, New York, 1997, pp. 77-87	
	65	Nemecek, G. M. et al., "Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor <i>in Vitro</i> and Neoinimal Proliferation <i>in Vivo</i> ," J. Pharmacol. Exp. Thera., 1989, 248, 1167-1174	
	66	Okada, T. et al., "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation," Neurosurgery, 1989, 25, 92-98	
	67	Popma, J. J. et al., "Atherectomy of right coronary ostial stenoses: initial and long-term results, technical features and histologic findings," Am J Cardiol., 1991 Feb 15; 67(5), 431-3	

EXAMINER

DATE CONSIDERED

Form PTO-1449 Modified		Docket No. CRD-5064	Application No. 10/785,519
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Michael O'Hara	
U.S. Department of Commerce Patent and Trademark Office		Filing Date February 24, 2004	Group 3731
		Confirmation No. 8314	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	68	Popma, J. J. et al., "Adjuncts to thrombolysis for myocardial reperfusion," Ann Intern Med., 1991 Jul 1, 115(1), 34-44	
	69	Popma, J. J. et al., "Clinical trials of restenosis after coronary angioplasty," Circulation, 1991 Sep, 84(3), 1426-1436	
	70	Popma, J. J. et al., "Clinical, angiographic and procedural correlates of quantitative coronary dimensions after directional coronary atherectomy," J Am Coll Cardiol., 1991 Nov 1, 18(5), 1183-1189	
	71	Powell, J. S. et al., "Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury," Science, 1989, 245, 186-188	
	72	Serruys, P. W. et al., "A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease," N Engl J Med, 1994 Aug 25; 331(8), 489-495	
	73	Serruys, P. W. et al., "Evaluation of ketanserine in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial," Circulation. 1993 Oct; 88(4 Pt 1), 1588-1601	
	74	Serruys, P. W. et al., "Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study," Circulation, 1996 Feb 1; 93(3), 412-422	
	75	Serruys, P. W. et al., "Randomized trials of coronary stenting," J Interv Cardiol, 1994 Aug; 7(4), 331	
	76	Serruys, P. W. et al., "Restenosis revisited: insights provided by quantitative coronary angiography," Am Heart J, 1993 Nov; 126(5), 1243-1267	
	77	Serruys, P. W. et al., "The bailout stent. Is a friend in need always a friend indeed?" Circulation, 1993 Nov; 88(5 Pt 1), 2455-2457	
	78	Simons, M. et al., "Antisense c-myc oligonucleotides inhibit intimal arterial smooth muscle cell accumulation <i>in vivo</i> ," Nature, 1992, 359, 67-70	
	79	Snow, A. D. et al., "Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells," Am. J. Pathol., 1990, 137, 313-330	
	80	Sollot, S. J. et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat," J. Clin. Invest., 1995, 95, 1869-1876	
	81	Tanaka, H. et al., "Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury," Circulation, 1993 Oct; 88(4 Pt 1), 1788-1803	

EXAMINER

DATE CONSIDERED

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CRD-5064	Application No. 10/785,519
		Applicant Michael O'Hara	
		Filing Date February 24, 2004	Group 3731
		Confirmation No. 8314	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	82	Tardif, et al., "Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group," N Engl J Med. 1997 Aug 7; 337(6), 365-372	
	83	Teirstein, P. S. et al., "Catheter-based radiotherapy to inhibit restenosis after coronary stenting," N Engl J Med., 1997 Jun 12; 336(24), 1697-1703	
	84	Weinberger, J. et al., "Intracoronary irradiation: dose response for the prevention of restenosis in swine," Int. J. Rad. Onc. Biol. Phys., 1996, 36, 767-775	
	85	Woo et al., Structurally Simple Trichostatin-A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors," J. Med Chem., 2002, 45, 2877-2885	
	86	Yokoi, H. et al., "Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial," J Am Coll Cardiol., 1997 Oct; 30(4), 855-862	

EXAMINER

DATE CONSIDERED

Page 1 of 1